JP2018514210A - ハイスループットbh3プロファイリング:少量の細胞でのbh3プロファイルのための迅速かつ拡大縮小可能な技術 - Google Patents
ハイスループットbh3プロファイリング:少量の細胞でのbh3プロファイルのための迅速かつ拡大縮小可能な技術 Download PDFInfo
- Publication number
- JP2018514210A JP2018514210A JP2017555780A JP2017555780A JP2018514210A JP 2018514210 A JP2018514210 A JP 2018514210A JP 2017555780 A JP2017555780 A JP 2017555780A JP 2017555780 A JP2017555780 A JP 2017555780A JP 2018514210 A JP2018514210 A JP 2018514210A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- peptide
- domain peptide
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 94
- 210000004027 cell Anatomy 0.000 claims abstract description 345
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 170
- 239000000872 buffer Substances 0.000 claims abstract description 109
- 238000012360 testing method Methods 0.000 claims abstract description 71
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 58
- 239000000853 adhesive Substances 0.000 claims abstract description 26
- 230000002438 mitochondrial effect Effects 0.000 claims abstract description 20
- 239000001963 growth medium Substances 0.000 claims abstract description 18
- 230000035945 sensitivity Effects 0.000 claims abstract description 18
- 230000008823 permeabilization Effects 0.000 claims abstract description 17
- 210000002966 serum Anatomy 0.000 claims abstract description 16
- 230000000861 pro-apoptotic effect Effects 0.000 claims abstract description 15
- 239000007787 solid Substances 0.000 claims abstract description 14
- 230000001070 adhesive effect Effects 0.000 claims abstract description 9
- 210000004748 cultured cell Anatomy 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 56
- 150000001875 compounds Chemical class 0.000 claims description 36
- 210000004881 tumor cell Anatomy 0.000 claims description 35
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 28
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 28
- 229940124597 therapeutic agent Drugs 0.000 claims description 23
- 108010035532 Collagen Proteins 0.000 claims description 17
- 102000008186 Collagen Human genes 0.000 claims description 17
- 229920001436 collagen Polymers 0.000 claims description 17
- 239000002246 antineoplastic agent Substances 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 238000005406 washing Methods 0.000 claims description 16
- 229940127089 cytotoxic agent Drugs 0.000 claims description 14
- 210000002744 extracellular matrix Anatomy 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 210000001519 tissue Anatomy 0.000 claims description 14
- 230000006907 apoptotic process Effects 0.000 claims description 13
- 238000012258 culturing Methods 0.000 claims description 13
- 230000001737 promoting effect Effects 0.000 claims description 13
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 12
- 238000000799 fluorescence microscopy Methods 0.000 claims description 11
- 101150082208 DIABLO gene Proteins 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 10
- 238000000386 microscopy Methods 0.000 claims description 9
- FYNNIUVBDKICAX-UHFFFAOYSA-M 1,1',3,3'-tetraethyl-5,5',6,6'-tetrachloroimidacarbocyanine iodide Chemical group [I-].CCN1C2=CC(Cl)=C(Cl)C=C2N(CC)C1=CC=CC1=[N+](CC)C2=CC(Cl)=C(Cl)C=C2N1CC FYNNIUVBDKICAX-UHFFFAOYSA-M 0.000 claims description 8
- RZCJYMOBWVJQGV-UHFFFAOYSA-N 2-naphthyloxyacetic acid Chemical compound C1=CC=CC2=CC(OCC(=O)O)=CC=C21 RZCJYMOBWVJQGV-UHFFFAOYSA-N 0.000 claims description 8
- 108010067306 Fibronectins Proteins 0.000 claims description 8
- 102000016359 Fibronectins Human genes 0.000 claims description 8
- 108010085895 Laminin Proteins 0.000 claims description 8
- 231100001143 noxa Toxicity 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 239000000411 inducer Substances 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 239000008191 permeabilizing agent Substances 0.000 claims description 7
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 claims description 6
- 230000001464 adherent effect Effects 0.000 claims description 6
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical group O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 claims description 6
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 claims description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 6
- 229930182490 saponin Natural products 0.000 claims description 6
- 150000007949 saponins Chemical class 0.000 claims description 6
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 5
- 102000003829 Adenylate kinase 2 Human genes 0.000 claims description 5
- 108090000115 Adenylate kinase 2 Proteins 0.000 claims description 5
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 claims description 5
- 101100232163 Mus musculus Htra2 gene Proteins 0.000 claims description 5
- 108010090804 Streptavidin Proteins 0.000 claims description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000010191 image analysis Methods 0.000 claims description 4
- FNEZBBILNYNQGC-UHFFFAOYSA-N methyl 2-(3,6-diamino-9h-xanthen-9-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1C2=CC=C(N)C=C2OC2=CC(N)=CC=C21 FNEZBBILNYNQGC-UHFFFAOYSA-N 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 3
- 108010087904 neutravidin Proteins 0.000 claims description 3
- 125000000647 trehalose group Chemical group 0.000 claims description 3
- 108010052832 Cytochromes Proteins 0.000 claims description 2
- 102000018832 Cytochromes Human genes 0.000 claims description 2
- 101710129178 Outer plastidial membrane protein porin Proteins 0.000 claims description 2
- 102100037820 Voltage-dependent anion-selective channel protein 1 Human genes 0.000 claims description 2
- 238000004020 luminiscence type Methods 0.000 claims description 2
- PFYWPQMAWCYNGW-UHFFFAOYSA-M [6-(dimethylamino)-9-(2-methoxycarbonylphenyl)xanthen-3-ylidene]-dimethylazanium;perchlorate Chemical compound [O-]Cl(=O)(=O)=O.COC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C21 PFYWPQMAWCYNGW-UHFFFAOYSA-M 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000005558 fluorometry Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 65
- 102000004196 processed proteins & peptides Human genes 0.000 description 35
- 102100030497 Cytochrome c Human genes 0.000 description 33
- 108010075031 Cytochromes c Proteins 0.000 description 33
- 229940079593 drug Drugs 0.000 description 30
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 29
- 201000002528 pancreatic cancer Diseases 0.000 description 29
- 201000011510 cancer Diseases 0.000 description 28
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 24
- 208000008443 pancreatic carcinoma Diseases 0.000 description 24
- 238000011282 treatment Methods 0.000 description 23
- 238000003556 assay Methods 0.000 description 18
- 239000000975 dye Substances 0.000 description 18
- 108010079882 Bax protein (53-86) Proteins 0.000 description 15
- 230000008034 disappearance Effects 0.000 description 15
- 231100000673 dose–response relationship Toxicity 0.000 description 15
- 101150084967 EPCAM gene Proteins 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 230000026683 transduction Effects 0.000 description 13
- 238000010361 transduction Methods 0.000 description 13
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 12
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 12
- 230000037452 priming Effects 0.000 description 12
- 238000013537 high throughput screening Methods 0.000 description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 108700000712 BH3 Interacting Domain Death Agonist Proteins 0.000 description 8
- 102100035740 BH3-interacting domain death agonist Human genes 0.000 description 8
- 101710138522 Bcl-2-binding component 3 Proteins 0.000 description 8
- 102100021573 Bcl-2-binding component 3, isoforms 3/4 Human genes 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 8
- 230000001640 apoptogenic effect Effects 0.000 description 8
- 230000030833 cell death Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000009368 gene silencing by RNA Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 7
- 239000006143 cell culture medium Substances 0.000 description 7
- 210000003470 mitochondria Anatomy 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 208000029742 colonic neoplasm Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 5
- 238000007877 drug screening Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 229920002873 Polyethylenimine Polymers 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940043355 kinase inhibitor Drugs 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 210000001700 mitochondrial membrane Anatomy 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000035572 chemosensitivity Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000011773 genetically engineered mouse model Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 230000005522 programmed cell death Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000012192 staining solution Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- -1 tetramethylrhodamine methyl ester Chemical class 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- 108090000323 DNA Topoisomerases Proteins 0.000 description 2
- 102000003915 DNA Topoisomerases Human genes 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- 101100071835 Danio rerio hoxb1b gene Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101100286123 Mus musculus Hoxa1 gene Proteins 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 2
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 229940122803 Vinca alkaloid Drugs 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 229960000548 alemtuzumab Drugs 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229960002756 azacitidine Drugs 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 229960002938 bexarotene Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- 229960001467 bortezomib Drugs 0.000 description 2
- 229960000455 brentuximab vedotin Drugs 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 210000004882 non-tumor cell Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 2
- 229960003452 romidepsin Drugs 0.000 description 2
- 108010091666 romidepsin Proteins 0.000 description 2
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229960004964 temozolomide Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960000303 topotecan Drugs 0.000 description 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 2
- 229960001183 venetoclax Drugs 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- 229960000237 vorinostat Drugs 0.000 description 2
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- JKMWZKPAXZBYEH-JWHWKPFMSA-N 5-[3-[4-(aminomethyl)phenoxy]propyl]-2-[(8e)-8-(1,3-benzothiazol-2-ylhydrazinylidene)-6,7-dihydro-5h-naphthalen-2-yl]-1,3-thiazole-4-carboxylic acid Chemical compound C1=CC(CN)=CC=C1OCCCC1=C(C(O)=O)N=C(C=2C=C3C(=N/NC=4SC5=CC=CC=C5N=4)/CCCC3=CC=2)S1 JKMWZKPAXZBYEH-JWHWKPFMSA-N 0.000 description 1
- DOCINCLJNAXZQF-LBPRGKRZSA-N 6-fluoro-3-phenyl-2-[(1s)-1-(7h-purin-6-ylamino)ethyl]quinazolin-4-one Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=NC2=CC=C(F)C=C2C(=O)N1C1=CC=CC=C1 DOCINCLJNAXZQF-LBPRGKRZSA-N 0.000 description 1
- XMVAWGSQPHFXKU-UHFFFAOYSA-N 7-[5-[[4-[4-(dimethylsulfamoyl)piperazin-1-yl]phenoxy]methyl]-1,3-dimethylpyrazol-4-yl]-1-(2-morpholin-4-ylethyl)-3-(3-naphthalen-1-yloxypropyl)indole-2-carboxylic acid Chemical compound C1CN(S(=O)(=O)N(C)C)CCN1C(C=C1)=CC=C1OCC1=C(C=2C=3N(CCN4CCOCC4)C(C(O)=O)=C(CCCOC=4C5=CC=CC=C5C=CC=4)C=3C=CC=2)C(C)=NN1C XMVAWGSQPHFXKU-UHFFFAOYSA-N 0.000 description 1
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000012666 Core Binding Factor Alpha 3 Subunit Human genes 0.000 description 1
- 108010079362 Core Binding Factor Alpha 3 Subunit Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 101100325747 Mus musculus Bak1 gene Proteins 0.000 description 1
- 101100437309 Mus musculus Bax gene Proteins 0.000 description 1
- 101100386053 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-3 gene Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- FMWLUWPQPKEARP-UHFFFAOYSA-N bromodichloromethane Chemical compound ClC(Cl)Br FMWLUWPQPKEARP-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000027721 electron transport chain Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000005710 macrocyclization reaction Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 1
- 229950004847 navitoclax Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000002220 organoid Anatomy 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000003836 solid-state method Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000035322 succinylation Effects 0.000 description 1
- 238000010613 succinylation reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
- G01N33/5079—Mitochondria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
Description
この出願は、米国特許法§119(e)の下、2015年4月27日に出願された米国仮出願第62/153,475号(この内容は、その全体が参考として本明細書に援用される)の利益を主張する。
アポトーシス促進性BCL−2 BH3ドメインペプチドは、以前にWO2014/047,342に記載されており、その内容は、参照により本明細書に組み込まれる。特に、アポトーシス促進性BCL−2 BH3ドメインペプチドは195アミノ酸長未満であり、例えば、150、100、75、50、35、25または15アミノ酸長未満またはそれと等しい。アポトーシス促進性BCL−2 BH3ペプチドの非限定的な例には、Bcl−2相互作用性細胞死媒介因子(BIM);その変異体(BIM AV);BH3相互作用性ドメインデスアゴニスト(BID);Bcl−2関連死プロモーター(BAD);NOXA;アポトーシスのp53アップレギュレーション型モジュレーター(PUMA);Bcl−2改変因子(BMF)およびハラキリ(HRK)が含まれる。
一部の態様では、本開示は、試験治療剤およびBH3ドメインペプチドを含むマルチウェル細胞培養プレートであって、各ウェルが接着性作用因子でコーティングされている、マルチウェル細胞培養プレートを提供する。一部の実施形態では、マルチウェルプレートは、プラスチックまたはガラスである。一部の実施形態では、マルチウェルプレートは、6、24、96、384または1536ウェルのアレイを含む。しかし、当業者は、マルチウェルプレートが、6、24、96、384または1536の倍数であるウェルの数を有するマルチウェルプレートのように、他の許容され得る多様な構成に構築され得ることを認識している。例えば、一部の実施形態では、マルチウェルプレートは、(1536の倍数である)3072ウェルのアレイを含む。
本発明の一部の態様は、BH3プロファイリングを行うためのキットを含む。一部の実施形態では、キットは、試験治療剤およびBH3ドメインペプチドを有するマルチウェルプレートを含む。一部の実施形態では、マルチウェルプレートの各ウェルは、接着性作用因子でコーティングされている。一部の実施形態では、接着性作用因子はECMタンパク質である。一部の実施形態では、ECMタンパク質は、コラーゲン1、ラミニン、コラーゲン4およびフィブロネクチンからなる群より選択される。一部の実施形態では、接着性作用因子は抗体である。例えば、細胞表面タンパク質に対する抗体は、マルチウェルプレートの各ウェルにコーティングされる場合がある。一部の実施形態では、接着性作用因子はストレプトアビジンである。
ダイナミックBH3プロファイリング(DBP)は、薬物が一次ヒト腫瘍(または患者由来異種移植片)のアポトーシス感受性をどのように変化させるかを決定する。現在使用されているダイナミックBH3プロファイリングの方法は、ウェル内において細胞を化学化合物で16〜24時間処理すること、細胞をウェルから取り上げること、遠心分離機を使用して細胞を培地から分離し、細胞をBH3プロファイリング緩衝液(DTEB)およびBH3プロファイリングペプチド中に入れることを伴う。内因性チトクロームcの消失を測定するが、有意な消失がある場合は、薬物が細胞をアポトーシスに向けて感作することを示す。これは、ヒト作業者のかなりの取り扱いおよび多数の腫瘍細胞を伴う骨の折れる工程であり、これらの両方が、克服すべき障壁となる。
1. 腫瘍を単一細胞懸濁物にする(機械的溶解および酵素消化による)。
この方法は、細胞が単一細胞懸濁物の状態になった後、ほとんどヒトの取り扱いを必要としない、ほぼ全自動化された手順である(図1)。この方法を、いくつかのがん細胞株(図3、4、11)、いくつかのPDXモデル(図5)、一次腫瘍(図6)、および遺伝的に操作されたマウスモデル(図7)に適用した。
Claims (40)
- 試験作用因子に対する細胞の感受性を予測する方法であって、
a)血清を有する培養培地中、試験作用因子の存在下および非存在下で、接着性固体表面上にて細胞を培養するステップ;
b)培養された前記細胞を、BH3プロファイリング緩衝液およびアポトーシス促進性BH3ドメインペプチドと接触させるステップ;
c)前記細胞におけるBH3ドメインペプチド誘導型ミトコンドリア外膜透過化(MOMP)の量を測定するステップ;および
d)前記試験作用因子の存在下で培養された前記細胞におけるBH3ドメインペプチド誘導型MOMPの量を、前記試験作用因子の非存在下で培養された前記細胞におけるBH3ドメインペプチド誘導型MOMPの量と比較するステップ
を含み、
前記試験作用因子の非存在下で培養された前記細胞におけるBH3ドメインペプチド誘導型MOMPの量と比較した、前記試験作用因子の存在下で培養された前記細胞におけるMOMPの増加が、前記細胞が前記試験作用因子に対して感受性であることを示す、方法。 - 前記細胞を前記BH3プロファイリング緩衝液および前記アポトーシス促進性BH3ドメインペプチドと接触させる前に、前記細胞から前記培養培地を洗浄するステップをさらに含む、請求項1に記載の方法。
- 前記BH3プロファイリング緩衝液が、2×、3×または4×の濃度で添加される、請求項1に記載の方法。
- 前記BH3プロファイリング緩衝液が、2×の濃度で添加され、BH3ドメインペプチド誘導型MOMPの量が、顕微鏡法によって測定される、請求項1に記載の方法。
- 前記BH3プロファイリング緩衝液が、3×または4×の濃度で添加され、BH3ドメインペプチド誘導型MOMPの量が、蛍光活性化セルソーティング(FACS)によって測定される、請求項1に記載の方法。
- 前記接着性固体表面が、1種または複数の接着促進化合物でコーティングされている、請求項1から5のいずれか一項に記載の方法。
- 前記1種または複数の接着促進化合物が、細胞外マトリックス(ECM)タンパク質である、請求項6に記載の方法。
- 前記ECMタンパク質が、コラーゲン1、ラミニン、コラーゲン4およびフィブロネクチンからなる群より選択される、請求項7に記載の方法。
- 前記ECMタンパク質が、動物組織に由来するECMタンパク質混合物である、請求項7に記載の方法。
- 前記1種または複数の接着促進化合物が抗体である、請求項6に記載の方法。
- 前記1種または複数の接着促進化合物が、ストレプトアビジンまたはニュートラアビジンである、請求項6に記載の方法。
- 前記BH3プロファイリング緩衝液が、トレハロース由来実験緩衝液(DTEB)またはマンニトール実験緩衝液(MEB)である、請求項1から11のいずれか一項に記載の方法。
- 前記BH3ドメインペプチドとの接触の後、その前、またはそれと同時に前記細胞が透過化される、請求項1から12のいずれか一項に記載の方法。
- 前記BH3プロファイリング緩衝液に透過化剤が補充される、請求項13に記載の方法。
- 前記透過化剤が、ジギトニンまたはサポニンである、請求項14に記載の方法。
- BH3ドメインペプチド誘導型MOMPの量が、i)電位差測定用色素と接触した細胞における前記電位差測定用色素の発光、またはii)ミトコンドリア膜間腔からの分子の放出を決定することによって測定される、請求項1から15のいずれか一項に記載の方法。
- BH3ドメインペプチド誘導型MOMPの量が、FACS、プレート蛍光定量法、蛍光イメージングまたは自動画像解析によって測定される、請求項1から15のいずれか一項に記載の方法。
- MOMPを測定する前に前記細胞を固定するステップをさらに含む、請求項1から17のいずれか一項に記載の方法。
- 固定された前記細胞が、電位差測定用色素と接触する、請求項18に記載の方法。
- 前記電位差測定用色素が、5,5’,6,6’−テトラクロロ−1,1’,3,3’−テトラエチルベンゾイミダゾリルカルボシアニンヨージド(JC−1)、ジヒドロローダミン123、テトラメチルローダミンメチルエステル(TMRM)またはテトラメチルローダミンエチルエステル(TMRE)である、請求項19に記載の方法。
- 固定された前記細胞が、チトクロームC、SMAC/Diablo、Omi、アデニル酸キナーゼ−2またはアポトーシス誘導因子に対する抗体と接触する、請求項18に記載の方法。
- 固定された前記細胞が、Tom20またはVDACに対する抗体と接触する、請求項18に記載の方法。
- 前記BH3ドメインペプチドが、BID、BIM、BAD、NOXA、PUMA、BMF、またはHRKポリペプチドのBH3ドメインに由来する、請求項1から22のいずれか一項に記載の方法。
- 前記BH3ドメインペプチドが、配列番号1〜15からなる群より選択される、請求項1から23のいずれか一項に記載の方法。
- 前記試験作用因子が治療剤である、請求項1から24のいずれか一項に記載の方法。
- 試験治療剤が化学療法剤である、請求項25に記載の方法。
- 前記細胞が初代ヒト腫瘍細胞である、請求項1から26のいずれか一項に記載の方法。
- 前記細胞が、患者由来異種移植片(PDX)から得られる、請求項1から26のいずれか一項に記載の方法。
- 前記細胞が培養ヒト細胞である、請求項1から26のいずれか一項に記載の方法。
- 前記細胞が、初代動物腫瘍細胞である、請求項1から26のいずれか一項に記載の方法。
- 前記細胞が、ヒトまたは動物組織に由来する健康な細胞である、請求項1から26のいずれか一項に記載の方法。
- 複数の試験作用因子を用いて繰り返される、請求項1から31のいずれか一項に記載の方法。
- 各ウェルが接着性作用因子でコーティングされている、試験治療剤およびBH3ドメインペプチドを含むマルチウェルプレート。
- 前記BH3ドメインペプチドが、BID、BIM、BAD、NOXA、PUMA、BMF、またはHRKポリペプチドのBH3ドメインに由来する、請求項33に記載のマルチウェルプレート。
- 前記BH3ドメインペプチドが、配列番号1〜15からなる群より選択される、請求項33に記載のマルチウェルプレート。
- 前記試験治療剤が化学療法剤である、請求項33から35のいずれか一項に記載のマルチウェルプレート。
- 前記接着性作用因子が細胞外マトリックス(ECM)タンパク質である、請求項33から36のいずれか一項に記載のマルチウェルプレート。
- 前記ECMタンパク質が、コラーゲン1、ラミニン、コラーゲン4およびフィブロネクチンからなる群より選択される、請求項37に記載のマルチウェルプレート。
- 前記接着性作用因子が抗体である、請求項33から36のいずれか一項に記載のマルチウェルプレート。
- 請求項33から39のいずれか一項に記載のマルチウェルプレートを含むキットであって、BH3プロファイリング緩衝液を収容するバイアルおよび治療剤に対する細胞の感受性を予測するために前記キットを使用するための指示をさらに含む、キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562153475P | 2015-04-27 | 2015-04-27 | |
US62/153,475 | 2015-04-27 | ||
PCT/US2016/029495 WO2016176288A1 (en) | 2015-04-27 | 2016-04-27 | High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018514210A true JP2018514210A (ja) | 2018-06-07 |
JP2018514210A5 JP2018514210A5 (ja) | 2019-07-04 |
JP6802185B2 JP6802185B2 (ja) | 2020-12-16 |
Family
ID=57198812
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017555779A Active JP6814745B2 (ja) | 2015-04-27 | 2016-04-27 | ダイナミックbh3プロファイリングを使用する毒性を評価するための組成物および方法 |
JP2017555780A Active JP6802185B2 (ja) | 2015-04-27 | 2016-04-27 | ハイスループットbh3プロファイリング:少量の細胞でのbh3プロファイルのための迅速かつ拡大縮小可能な技術 |
JP2020200805A Withdrawn JP2021036915A (ja) | 2015-04-27 | 2020-12-03 | ダイナミックbh3プロファイリングを使用する毒性を評価するための組成物および方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017555779A Active JP6814745B2 (ja) | 2015-04-27 | 2016-04-27 | ダイナミックbh3プロファイリングを使用する毒性を評価するための組成物および方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020200805A Withdrawn JP2021036915A (ja) | 2015-04-27 | 2020-12-03 | ダイナミックbh3プロファイリングを使用する毒性を評価するための組成物および方法 |
Country Status (7)
Country | Link |
---|---|
US (4) | US20180120297A1 (ja) |
EP (2) | EP3288964B1 (ja) |
JP (3) | JP6814745B2 (ja) |
AU (2) | AU2016253957C1 (ja) |
CA (2) | CA2983022C (ja) |
HK (2) | HK1252058A1 (ja) |
WO (2) | WO2016176288A1 (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004022580A2 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
CA2645853A1 (en) | 2006-03-31 | 2007-11-01 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
WO2014047342A1 (en) * | 2012-09-19 | 2014-03-27 | Dana-Farber Cancer Institute, Inc. | Dynamic bh3 profiling |
CA2922503C (en) | 2013-09-19 | 2021-10-26 | Dana-Farber Cancer Institute, Inc. | Methods of bh3 profiling |
CA2974240A1 (en) | 2015-01-12 | 2016-07-21 | Eutropics Pharmaceuticals, Inc. | Context dependent diagnostics test for guiding cancer treatment |
CA2979999A1 (en) | 2015-03-18 | 2016-09-22 | Massachusetts Institute Of Technology | Selective mcl-1 binding peptides |
AU2016252609B2 (en) | 2015-04-20 | 2022-06-30 | Sumitomo Pharma Oncology, Inc. | Predicting response to alvocidib by mitochondrial profiling |
EP3288964B1 (en) | 2015-04-27 | 2024-02-21 | Dana-Farber Cancer Institute, Inc. | High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells |
US9758539B2 (en) | 2015-05-18 | 2017-09-12 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs having increased bioavailability |
CN108289861B (zh) | 2015-08-03 | 2021-11-02 | 大日本住友制药肿瘤公司 | 用于治疗癌症的组合疗法 |
US11198715B2 (en) | 2016-07-22 | 2021-12-14 | Massachusetts Institute Of Technology | Selective Bfl-1 peptides |
US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
WO2018119000A1 (en) | 2016-12-19 | 2018-06-28 | Tolero Pharmaceuticals, Inc. | Profiling peptides and methods for sensitivity profiling |
JP7196160B2 (ja) | 2017-09-12 | 2022-12-26 | スミトモ ファーマ オンコロジー, インコーポレイテッド | Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン |
EP3852783A1 (en) | 2018-09-17 | 2021-07-28 | Massachusetts Institute of Technology | Peptides selective for bcl-2 family proteins |
MX2021006544A (es) | 2018-12-04 | 2021-07-07 | Sumitomo Pharma Oncology Inc | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. |
US20220163510A1 (en) * | 2019-02-26 | 2022-05-26 | Dana-Farber Cancer Institute, Inc. | Live cell imaging dynamic bh3 profiling |
WO2020191326A1 (en) | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (aml) with venetoclax failure |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005130867A (ja) * | 2005-02-16 | 2005-05-26 | Mitokor | ミトコンドリア内カルシウムを使用するスクリーニングアッセイ |
JP2006520606A (ja) * | 2003-03-19 | 2006-09-14 | アルファ ワッサーマン インコーポレイテッド | 細胞内成分の分離および蓄積、およびそれに由来するタンパク質 |
JP2009240173A (ja) * | 2008-03-28 | 2009-10-22 | Univ Of Tokushima | パーキン蛋白の新規糖化因子 |
JP2009543044A (ja) * | 2006-07-07 | 2009-12-03 | ヒュン−キ・キム | Hccr−1を含む乳癌予後マーカー及び肥満誘導組成物 |
JP2012529890A (ja) * | 2009-06-11 | 2012-11-29 | ミネルバ バイオテクノロジーズ コーポレーション | 幹細胞及び前駆細胞を培養する方法 |
WO2013170176A2 (en) * | 2012-05-10 | 2013-11-14 | Eutropics Pharmaceuticals, Inc. | Surrogate functional diagnostics test for cancer |
WO2013188978A1 (en) * | 2012-06-20 | 2013-12-27 | Cytospan Technologies Corporation | Apparatus and method for quantification of replicative lifespan and observation of senescene |
WO2014047342A1 (en) * | 2012-09-19 | 2014-03-27 | Dana-Farber Cancer Institute, Inc. | Dynamic bh3 profiling |
JP2014081365A (ja) * | 2012-09-26 | 2014-05-08 | Fujita Gakuen | 細胞表面タンパクを抗原とする抗体を測定する方法 |
WO2015010094A1 (en) * | 2013-07-18 | 2015-01-22 | Eutropics Pharmaceuticals, Inc. | Differential bh3 mitochondrial profiling |
WO2015042249A1 (en) * | 2013-09-19 | 2015-03-26 | Dana-Farber Cancer Institute, Inc. | Methods of bh3 profiling |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5670617A (en) | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Hiv感染治療のための異種複合抗体 |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
CA2140638C (en) | 1992-07-24 | 2010-05-04 | Raju Kucherlapati | Generation of xenogeneic antibodies |
EP0752248B1 (en) | 1992-11-13 | 2000-09-27 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
ATE365808T1 (de) | 1995-07-28 | 2007-07-15 | Marie Curie Cancer Care | Transportproteine und deren verwendungen |
EP0799422A1 (en) | 1995-10-24 | 1997-10-08 | Sangstat Medical Corporation | Anti alpha-galactosyl screening technique |
US5965703A (en) | 1996-09-20 | 1999-10-12 | Idun Pharmaceuticals | Human bad polypeptides, encoding nucleic acids and methods of use |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
JP2001524301A (ja) | 1997-09-17 | 2001-12-04 | ザ・ワルター・アンド・エリザ・ホール・インスティテュート・オヴ・メディカル・リサーチ | 新規治療用分子 |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
WO2000059526A1 (en) | 1999-04-07 | 2000-10-12 | Thomas Jefferson University | Enhancement of peptide cellular uptake |
WO2001012661A2 (en) | 1999-08-16 | 2001-02-22 | The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healthand Human Services, The National Institutes Of Health | RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS |
WO2002020568A2 (en) | 2000-09-06 | 2002-03-14 | Abbott Laboratories | Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins |
WO2002069995A2 (en) | 2001-02-16 | 2002-09-12 | Medical College Of Georgia Research Institute, Inc. | Use of trail and antiprogestins for treating cancer |
WO2003040168A2 (en) * | 2001-11-06 | 2003-05-15 | Enanta Pharmaceuticals, Inc. | Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype |
JP2005518393A (ja) | 2001-12-21 | 2005-06-23 | アリアス リサーチ、インコーポレイテッド | 個別化抗癌抗体 |
WO2004022580A2 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
WO2004058804A1 (en) | 2002-12-24 | 2004-07-15 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
ES2586387T3 (es) | 2003-11-05 | 2016-10-14 | Dana-Farber Cancer Institute, Inc. | Péptidos alfa helicoidales adecuados para activar o inhibir la muerte celular |
US7714005B2 (en) | 2004-12-22 | 2010-05-11 | The Ohio State University Research Foundation | Small molecule Bcl-xL/Bcl-2 binding inhibitors |
WO2006099667A1 (en) | 2005-03-21 | 2006-09-28 | The Walter And Eliza Hall Institute Of Medical Research | Prophylactic and therapeutic agents and uses therefor |
WO2007016254A2 (en) | 2005-07-27 | 2007-02-08 | The Board Of Trustees Of The University Of Arkansas | Antineoplastic activities of ellipticine and its derivatives |
CA2645853A1 (en) | 2006-03-31 | 2007-11-01 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
US8518635B2 (en) | 2006-06-12 | 2013-08-27 | The J. David Gladstone Institutes | Regulation of protein activity by reversible acetylation |
WO2008021484A2 (en) * | 2006-08-16 | 2008-02-21 | Eutropics Pharmaceuticals | Assay system to identify therapeutic agents |
WO2008152405A2 (en) | 2007-06-15 | 2008-12-18 | The Queen's University Of Belfast | Protein complexes comprising bh3 peptides and voltage dependent anion channel (vdac) peptides as well as uses thereof for the treatment of proliferative diseases |
EP2200653A2 (en) | 2007-09-10 | 2010-06-30 | University of Massachusetts | Mitochondria-targeted anti-tumour agents |
CA2700925C (en) * | 2007-09-26 | 2016-08-23 | Dana Farber Cancer Institute | Methods and compositions for modulating bcl-2 family polypeptides |
WO2010147961A1 (en) | 2009-06-15 | 2010-12-23 | Precision Therapeutics, Inc. | Methods and markers for predicting responses to chemotherapy |
US20130122492A1 (en) | 2011-11-14 | 2013-05-16 | Kellbenx Inc. | Detection, isolation and analysis of rare cells in biological fluids |
EP3288964B1 (en) | 2015-04-27 | 2024-02-21 | Dana-Farber Cancer Institute, Inc. | High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells |
US11092602B2 (en) | 2015-07-06 | 2021-08-17 | Whitehead Institute For Biomedical Research | Methods and compositions relating to proteasome inhibitor resistance |
US20220163510A1 (en) | 2019-02-26 | 2022-05-26 | Dana-Farber Cancer Institute, Inc. | Live cell imaging dynamic bh3 profiling |
-
2016
- 2016-04-27 EP EP16787039.3A patent/EP3288964B1/en active Active
- 2016-04-27 EP EP16787045.0A patent/EP3289094A4/en active Pending
- 2016-04-27 CA CA2983022A patent/CA2983022C/en active Active
- 2016-04-27 JP JP2017555779A patent/JP6814745B2/ja active Active
- 2016-04-27 WO PCT/US2016/029495 patent/WO2016176288A1/en active Application Filing
- 2016-04-27 JP JP2017555780A patent/JP6802185B2/ja active Active
- 2016-04-27 CA CA2983024A patent/CA2983024A1/en active Pending
- 2016-04-27 US US15/569,851 patent/US20180120297A1/en not_active Abandoned
- 2016-04-27 AU AU2016253957A patent/AU2016253957C1/en active Active
- 2016-04-27 US US15/568,994 patent/US10761086B2/en active Active
- 2016-04-27 WO PCT/US2016/029510 patent/WO2016176299A1/en active Application Filing
- 2016-04-27 AU AU2016255749A patent/AU2016255749B2/en active Active
-
2018
- 2018-09-05 HK HK18111390.3A patent/HK1252058A1/zh unknown
- 2018-09-05 HK HK18111387.8A patent/HK1252055A1/zh unknown
-
2020
- 2020-07-27 US US16/939,736 patent/US11867688B2/en active Active
- 2020-12-03 JP JP2020200805A patent/JP2021036915A/ja not_active Withdrawn
-
2021
- 2021-02-26 US US17/186,344 patent/US20210255167A1/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006520606A (ja) * | 2003-03-19 | 2006-09-14 | アルファ ワッサーマン インコーポレイテッド | 細胞内成分の分離および蓄積、およびそれに由来するタンパク質 |
JP2005130867A (ja) * | 2005-02-16 | 2005-05-26 | Mitokor | ミトコンドリア内カルシウムを使用するスクリーニングアッセイ |
JP2009543044A (ja) * | 2006-07-07 | 2009-12-03 | ヒュン−キ・キム | Hccr−1を含む乳癌予後マーカー及び肥満誘導組成物 |
JP2009240173A (ja) * | 2008-03-28 | 2009-10-22 | Univ Of Tokushima | パーキン蛋白の新規糖化因子 |
JP2012529890A (ja) * | 2009-06-11 | 2012-11-29 | ミネルバ バイオテクノロジーズ コーポレーション | 幹細胞及び前駆細胞を培養する方法 |
WO2013170176A2 (en) * | 2012-05-10 | 2013-11-14 | Eutropics Pharmaceuticals, Inc. | Surrogate functional diagnostics test for cancer |
WO2013188978A1 (en) * | 2012-06-20 | 2013-12-27 | Cytospan Technologies Corporation | Apparatus and method for quantification of replicative lifespan and observation of senescene |
WO2014047342A1 (en) * | 2012-09-19 | 2014-03-27 | Dana-Farber Cancer Institute, Inc. | Dynamic bh3 profiling |
JP2014081365A (ja) * | 2012-09-26 | 2014-05-08 | Fujita Gakuen | 細胞表面タンパクを抗原とする抗体を測定する方法 |
WO2015010094A1 (en) * | 2013-07-18 | 2015-01-22 | Eutropics Pharmaceuticals, Inc. | Differential bh3 mitochondrial profiling |
WO2015042249A1 (en) * | 2013-09-19 | 2015-03-26 | Dana-Farber Cancer Institute, Inc. | Methods of bh3 profiling |
Non-Patent Citations (3)
Title |
---|
ACS CHEM. BIOL., 2014, VOL.9, P.1962-1968, JPN6020008593, ISSN: 0004227260 * |
CANCER DISCOV., 2014, VOL.4, P.362-375, JPN6020008597, ISSN: 0004227262 * |
CELL, 2015.02.26, VOL.160, P.977-989, JPN6020008595, ISSN: 0004227261 * |
Also Published As
Publication number | Publication date |
---|---|
AU2016255749B2 (en) | 2021-10-14 |
JP6802185B2 (ja) | 2020-12-16 |
WO2016176288A1 (en) | 2016-11-03 |
US11867688B2 (en) | 2024-01-09 |
EP3289094A4 (en) | 2018-10-31 |
HK1252058A1 (zh) | 2019-05-10 |
CA2983022A1 (en) | 2016-11-03 |
US20210255167A1 (en) | 2021-08-19 |
US20180120297A1 (en) | 2018-05-03 |
AU2016253957A1 (en) | 2017-10-19 |
WO2016176299A1 (en) | 2016-11-03 |
EP3288964B1 (en) | 2024-02-21 |
US20180128813A1 (en) | 2018-05-10 |
CA2983024A1 (en) | 2016-11-03 |
AU2016255749A1 (en) | 2017-10-19 |
US20210041419A1 (en) | 2021-02-11 |
CA2983022C (en) | 2023-03-07 |
HK1252055A1 (zh) | 2019-05-10 |
EP3288964A4 (en) | 2018-10-31 |
AU2016253957B2 (en) | 2020-10-22 |
JP2018520638A (ja) | 2018-08-02 |
US10761086B2 (en) | 2020-09-01 |
AU2016253957C1 (en) | 2021-04-01 |
EP3289094A1 (en) | 2018-03-07 |
EP3288964A1 (en) | 2018-03-07 |
JP2021036915A (ja) | 2021-03-11 |
JP6814745B2 (ja) | 2021-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11867688B2 (en) | High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells | |
EP2660601B1 (en) | Methods for detecting molecular interactions | |
Mendes et al. | Optimization of the magnetic recovery of hits from one-bead–one-compound library screens | |
US20220163510A1 (en) | Live cell imaging dynamic bh3 profiling | |
Ahn et al. | Searching for pathogenic gene functions to cervical cancer | |
KR20030094404A (ko) | 프로테옴 칩을 사용한 단백질 활성의 포괄적인 분석 | |
EP3123175A1 (en) | Method for identifying a biomarker indicative of a reduced drug response using a thermal shift assay | |
CN112964881A (zh) | 一种高通量高灵敏度的单细胞转染蛋白质分析芯片 | |
Guise et al. | Approaches for studying the subcellular localization, interactions, and regulation of histone deacetylase 5 (HDAC5) | |
Loo et al. | Repair of CFTR folding defects with correctors that function as pharmacological chaperones | |
Rees et al. | Identification of the cis‑molecular neighbours of the immune checkpoint protein B7‑H4 in the breast cancer cell‑line SK‑BR‑3 by proteomic proximity labelling | |
KR101444995B1 (ko) | 세포질 단백질의 단백질-단백질 상호작용을 확인하는 방법 | |
WO2007058987A1 (en) | Methods of identifying compounds that inhibit notch cleavage | |
KR101453554B1 (ko) | 물질의 상호작용을 탐색하는 방법 및 키트 | |
KR20140137088A (ko) | 연자성미세구조물을 이용한 리간드의 스크리닝 시스템 및 그 용도 | |
JP2009250652A (ja) | 細胞内移行性速度を測定することによる機能性物質のスクリーニング法 | |
EP2981616B1 (en) | Solid phase transfection of proteins and nucleic acids | |
KR20220086609A (ko) | 반응성 친화도 탐침-상호작용 발견 플랫폼 | |
KR101119995B1 (ko) | 단백질 상호작용 억제제 선별방법 | |
KR20140043418A (ko) | 벤조안트라센 오염 검출을 위한 마커 및 키트 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190426 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190426 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190529 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200305 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200605 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201111 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201126 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6802185 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |